DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
AbbVie - 1 ImmunoGen - 1 Michael Schmidt - 1 Mersana - 1 David Nierengarten - 1 Anna Protopapas - 1 UpRi - 1 Khushi - 1
Top related locs:
ADCs Bengaluru
Top related orgs:
Mersana Therapeutics - 2 Biotech - 1 ADC Therapeutics - 1 P Biotech ETF - 1 Nasdaq Biotechnology - 1 ImmunoGen - 1 Pfizer - 1 Merck - 1

Search resuls for: "Mersana"


2 mentions found


☆ Biotech stocks jump on AbbVie deal to buy cancer drugmaker ImmunoGen for $10 billion
  + stars: | 2023-11-30 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +1 min
Biotech stocks rose Thursday as AbbVie announced plans to buy cancer drug developer ImmunoGen for $10.1 billion. ImmunoGen develops cancer drugs called antibody-drug conjugates, or ADCs, which are designed to directly kill cancer cells and spare healthy ones. Shares of other biotech companies developing ADCs, which are among the hottest areas in the pharmaceutical industry, jumped on the news of the buyout. The SPDR S&P Biotech ETF , which focuses on small and midsize biotech companies, rose 3% Thursday. Under the terms of the deal, AbbVie will pay $31.26 a share in cash for ImmunoGen, a roughly 95% premium to Wednesday's closing price.
Persons: AbbVie, ImmunoGen, Michael Schmidt Organizations: Biotech, Mersana Therapeutics, ADC Therapeutics, P Biotech ETF, Nasdaq Biotechnology, ImmunoGen, Pfizer, Merck, CNBC PRO Locations: ADCs
☆ US FDA halts enrollment in Mersana's cancer drug studies, shares drop
  + stars: | 2023-06-15 | by ( Khushi Mandowara | ) www.reuters.com   time to read: +1 min
June 15 (Reuters) - Mersana Therapeutics (MRSN.O) said on Thursday the U.S. Food and Drug Administration (FDA) had paused enrollment in two studies of its ovarian cancer drug after five deaths in bleeding-related events, sending shares of the company tumbling. Mersana said the cause of the bleeding events was under investigation, but patients who are already enrolled in the studies will continue to receive the treatment. Mersana said it expects the FDA to ask for a comprehensive assessment of the safety data of upifitamab rilsodotin (UpRi), the company's lead drug. "Work is now underway to compile further analyses that may inform FDA," Mersana CEO Anna Protopapas said. UpRi is also being tested in another ovarian cancer study, which has already completed enrollment, and data from it is expected in August.
Persons: Mersana, David Nierengarten, Anna Protopapas, UpRi, Khushi, Savio D'Souza, Shinjini Organizations: Mersana Therapeutics, U.S . Food, Drug Administration, Wedbush Securities, FDA, Thomson Locations: Bengaluru
0 next >>
Total: 2